1Molecular Pathology of Cystic Fibrosis Clinical Research Group, Clinic for Paediatric Pneumology, Allergology, and Neonatology, OE 6710, Hannover Medical School, Hannover, Germany 2Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Centre for Lung Research, Hannover, Germany
OPEN PEER REVIEW
REVIEWER STATUS
Abstract
The versatile and ubiquitous Pseudomonas aeruginosa is an opportunistic pathogen causing acute and chronic infections in predisposed human subjects. Here we review recent progress in understanding P. aeruginosa population biology and virulence, its cyclic di-GMP-mediated switches of lifestyle, and its interaction with the mammalian host as well as the role of the type III and type VI secretion systems in P. aeruginosa infection.
Keywords
Pseudomonas aeruginosa, type III secretion system, T3SS, type VI secretion system, T6SS, c-di-GMP
Corresponding author:
Burkhard Tümmler
Competing interests:
The authors declare that they have no competing interests.
Grant information:
The authors’ work on P. aeruginosa genomics, microevolution, and pathogenicity has been supported by the Bundesministerium für Forschung und Technologie BMBF (FKZ 0315827D) and the Deutsche Forschungsgemeinschaft (SFB 900, projects A2 and Z1).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Pseudomonas aeruginosa is a metabolically versatile ubiquitous gamma-proteobacterium that thrives in soil and aquatic habitats and colonizes the animate surfaces of plants, animals, and humans1. P. aeruginosa may cause multiple infections in man that vary from local to systemic and from benign to life threatening. During the last few decades, the cosmopolitan Gram-negative bacterium has become one of the most frequent causative agents of nosocomial infections associated with substantial morbidity and mortality2. Pneumonia and sepsis in intensive care unit (ICU) patients still have a bleak prognosis3. Chronic airway infections with P. aeruginosa are a major cause of morbidity in people with cystic fibrosis (CF) or chronic obstructive pulmonary disease (COPD)3–5. Here we report on recent advances in the understanding of host–pathogen interactions with particular emphasis on infections with P. aeruginosa in humans.
Differential pathogenicity of clone types
P. aeruginosa is equipped with a large repertoire of virulence determinants (Table 1) and a complex regulatory network of intracellular and intercellular signals6,7 that allow the bacteria to adapt to and thrive in an animate niche and to escape host defence. This ability, however, varies from clone to clone and from strain to strain in the worldwide P. aeruginosa population. When representative isolates of the 20 most common clones in clinical and environmental habitats (Figure 1) were tested in three established infection models, i.e. an acute infection of murine airways, lettuce, and wax moth larvae, an unexpected gradient of pathogenicity was observed8. Under the conditions of the standardized acute airway infection model in the mouse, the full spectrum of possible host responses to P. aeruginosa was seen that ranged from unimpaired health to 100% lethality. Likewise, similar gradients of virulence were observed with plant and insect hosts whereby the pathogenicity of most strains differed by host. A strain could be innocuous for the mouse but highly pathogenic for the lettuce, and vice versa.
Table 1. Virulence effectors of Pseudomonas aeruginosa*.
Name
Activity and function
ArpA
Alkaline protease, zinc metalloprotease; degrades host immune complements C1q, C2, and C3 and cytokines interferon (IFN)-γ and tumour necrosis factor (TNF)-α
Cif
Cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor, epoxide hydrolase; promotes sustained inflammation by hydrolysing the paracrine signal 14,15-epoxyeicosatrienoic acid that stimulates neutrophils to produce the proresolving lipid mediator 15-epi lipoxin A4; Cif increases the ubiquitination and lysosomal degradation of some ATP-binding cassette transporters (ABC) including CFTR, P-glycoprotein, and TAP1
ExlA
Exolysin A, a pore-forming toxin that induces plasma membrane rupture in epithelial, endothelial, and immune cells
ExoS
Bifunctional toxin with Rho GTPase-activating protein (RhoGAP) activity and ADP-ribosyltransferase (ADPRT) activity; it blocks the reactive oxygen species burst in neutrophils by ADP-ribosylation of Ras, thereby preventing the activation of phosphoinositide-3-kinase (PI3K), which is required to stimulate the phagocytic NADPH-oxidase
ExoT
Bifunctional toxin with RhoGAP activity and ADPRT activity; it impairs the production of reactive oxygen species burst in neutrophils and promotes the apoptosis of host cells by transforming host protein Crk by ADP-ribosylation into a cytotoxin and by activation of the intrinsic mitochondrial apoptotic pathway
ExoU
Phospholipase A2, releases fatty acids from a broad range of phospholipids and lysophospholipids; it becomes activated by interaction with ubiquitin or ubiquitinylated proteins in the cytosol of the host cell
ExoY
Nucleotidyl cyclase with preference for cGMP and cUMP production; it becomes activated by binding to filamentous actin
LasA
Zinc metalloprotease of the M23A family; it enhances elastolytic activity of LasB
LasB
Zinc metalloprotease with strong elastolytic activity
PlcH
Haemolytic phospholipase C that releases phosphate esters from sphingomyelin and phosphatidylcholine
PlcN
Non-haemolytic phospholipase C that releases phosphate esters from phosphatidylserine and phosphatidylcholine
PldA
Trans-kingdom toxin, phospholipase D, facilitates intracellular invasion of host eukaryotic cells by activation of the PI3K/ Akt pathway
PldB
Trans-kingdom toxin, phospholipase D, facilitates intracellular invasion of host eukaryotic cells by activation of the PI3K/ Akt pathway
PrpL
Class IV protease, lysine endoproteinase, degrades proteins such as complement, immunoglobulins, elastin, lactoferrin, and transferrin
Pyocyanin
Redox-active zwitterion that is cytotoxic
Rhamnolipids
Chemically heterogeneous group of monorhamnolipids and dirhamnolipids that are also biosurfactants and cause haemolysis and lysis of immune effector cells
Tox A
Exotoxin A, a toxin with ADPRT activity; it mediates its entry into target host cells through its cell-binding domain, then ADP-ribosylates host elongation factor 2 (EF-2) to block protein synthesis through its enzymatic domain
TplE
Trans-kingdom toxin, phospholipase A1, disrupts the endoplasmic reticulum and thereby promotes autophagy by the activation of the unfolded protein response
*The Table lists proven virulence effectors in infections of mammals
Figure 1. Phylogenetic tree of Pseudomonas aeruginosa strains representing the 20 most common clones in the global P. aeruginosa population8,9.
Clones are designated by a hexadecimal code representing single nucleotide polymorphisms (SNPs) at seven conserved loci of the core genome and the subtypes of exoU/exoS and fliC9. The B420 clone represents the PA7-outlier group, D421, EC21, F469, E429, and F429 the ExoU-positive clade, and all other clones the ExoS-positive clade. The tree is based on paired genome-wide comparisons of SNPs in the core genome8. The scale indicates the sequence diversity. Reproduced from Figure 5 of 8.
The differential genetic repertoire of clones maintains a host-specific gradient of virulence in the P. aeruginosa population whereby differential sets of pathogenicity factors and mechanisms are employed to conquer the diverse animate niches. In other words, the fitness of a clone to colonize and to persist differs by habitat. This conclusion is supported by real-world data. Close to 3,000 spatiotemporally unrelated isolates from the environment, acute human infection, and chronically colonized COPD and CF airways were genotyped with a marker microarray yielding 300-odd clone genotypes9. The 20 most frequent clones had an absolute share of 44%, indicating that the P. aeruginosa population is dominated by few epidemic clonal lineages. The most abundant clones like C or PA14 were detected in all habitats, albeit at different frequencies10. On the other hand, the proportion of habitat-specific clones was 25% in COPD, 32% in acute infections, 39% in the environment, and 54% in CF, indicating that the CF lungs select for rare clones that can withstand exposure to a hostile immune system and regular antimicrobial chemotherapy and that the soil and aquatic habitats accommodate a subgroup of clones that cannot colonize a human niche. The spectrum of clones was broader in COPD and CF lungs than in the multiple niches of acute infections, implying that the airways of a predisposed host can be colonized by more clone types than the organs of a previously healthy and immunocompetent host that suffers from an acute insult. In summary, a human habitat can be colonized by some generalists like clone C or PA14 and some minor clones that have a low prevalence in the global population but are endowed with clone-specific features of fitness and/or pathogenicity to become a dominant member in the particular human niche. Since most research has focused on clinical isolates, the analysis of isolates from non-clinical habitats may reveal features yet unknown for P. aeruginosa.
Non-coding RNAs
The Pseudomonas genome database11 (20 June 2017) lists 37 non-coding RNAs in the genome of reference strain PAO1. These small RNAs (sRNA) have regulatory functions. Prominent examples are RsmY, RsmZ, or CrcZ, which are master regulators of bacterial lifestyle, biofilm formation, and carbon metabolism12–15. Recently, the first example of trans-kingdom biological activity of a regulatory P. aeruginosa sRNA was described16. P. aeruginosa bacteria released outer membrane vesicles (OMVs) containing thousands of unique sRNA fragments. The OMVs fused with and delivered sRNAs into mammalian cells, thereby attenuating neutrophil recruitment and the secretion of pro-inflammatory cytokines.
Type III and type VI secretion systems
The type III secretion system (T3SS) and its effectors are the major virulence determinants of P. aeruginosa17. The T3SS forms a needle that directly injects virulence effectors (ExoS, T, U, and Y) into the host cell. The ADP-ribosyltransferase (ADPRT) ExoS18,19 and the phospholipase A2 ExoU20,21 occur almost mutually exclusively in P. aeruginosa so that the population is currently differentiated into a major ExoS-positive clade, a minor ExoU-positive clade, and a minute T3SS-negative clade lacking both ExoS and ExoU9,22. ExoU and its homologue PlpD23,24, which is secreted through the type V secretion system, are lipolytic enzymes of the patatin-like protein family. ExoU is highly cytotoxic and more virulent than ExoS in infection models, which correlates with the higher morbidity of acute infections with ExoU-positive than with ExoS-positive strains. ExoS and ExoT consist of an N-terminal GTPase-activating protein (GAP) domain and a C-terminal ADPRT domain. Both ExoS and ExoT disrupt the signalling pathway responsible for the activation and assembly of the phagocytic NADPH oxidase and thereby block the production of reactive oxygen species (Table 1)25. ExoT moreover promotes the apoptosis of host cells. The GAP domain of ExoT triggers the mitochondrial intrinsic pathway of apoptosis26, and ADPRT domain activity transforms the focal adhesion adaptor protein Crk of the host cell into a cytotoxin that induces a form of programmed cell death known as anoikis, which occurs in cells when they detach from the surrounding extracellular matrix27. The pathogenicity of ExoS, ExoU, and ExoT is well established, but the role of ExoY during infections still needs to be elucidated28–31. ExoY synthesizes numerous cyclic nucleotides (cNMPs)32. The uncommon cUMP turned out to be the most prominent cNMP generated in the lungs of mice infected with ExoY overexpressing P. aeruginosa. cUMP was detectable in body fluids, suggesting that this unusual cNMP in contrast to cAMP or cGMP is not rapidly degraded and thus may interfere with the second messenger signalling of the host.
The T3SS-negative clade represents three groups of taxonomic outliers with above-average sequence diversity8,22,33. This, however, does not imply that these strains are innocuous. Firstly, isolates have transferred genomic islands to major ExoS-positive clonal lineages and thereby supplied the recipients with determinants of resistance to antimicrobials34. Secondly, some strains harbour the recently discovered two-partner secretion system ExlAB35,36. ExlB exports a pore-forming toxin called exolysin (ExlA), which induces plasma membrane rupture in epithelial, endothelial, and immune cells but not in erythrocytes. Thirdly, these outliers, like all other ExoS- or ExoU-positive P. aeruginosa strains, possess type VI secretion systems (T6SS).
The T6SS is a bacterial nanomachine that shares similarity with the puncturing device of bacteriophages37,38. The three separate H1-, H2-, and H3-T6SS translocate proteins between cells by a mechanism analogous to phage tail contraction. The H1-T6SS delivers the three toxins Tse1–3, which kill bacterial competitors inhabiting the same niche. The H2- and H3-T6SS target both prokaryotic and eukaryotic cells, i.e. they translocate trans-kingdom effectors39–44. These toxins exert antibacterial activity and facilitate intracellular invasion of host eukaryotic cells (Table 1). The phospholipase TplE, for example, disrupts the endoplasmic reticulum and thereby promotes autophagy by the activation of the unfolded protein response40,42–44.
Control of lifestyle by cyclic di-GMP signalling
P. aeruginosa can switch between a motile and a sessile lifestyle and can modulate the secretion of virulence effectors by a plethora of transcription factors, two-component systems, non-coding RNAs, and quorum-sensing networks6,45. Research in the last few years has focused on the complex signalling pathways mediated by the second messenger cyclic di-GMP (c-di-GMP)46,47. P. aeruginosa possesses more than 40 diguanylate cyclases and c-di-GMP-degrading phosphodiesterases, the specificities of which are currently under investigation46,47.
Elevated levels of c-di-GMP promote biofilm formation typical for chronic infections and repress flagellum-driven swarming motility typical for acute infections and vice versa. The master transcription regulator FleQ, for example, activates the transcription of flagellar genes when intracellular c-di-GMP levels are low, but upon binding of c-di-GMP FleQ converts to an activator of the expression of genes involved in biofilm formation such as the adhesin CdrAB or the exopolysaccharides Psl and Pel48,49. The binding of c-di-GMP leads to major conformational rearrangements in FleQ, which reasonably explains the dual role of FleQ in promoting both the sessile and the motile lifestyles dependent on c-di-GMP levels.
The third major exopolysaccharide in P. aeruginosa biofilms is alginate, a polymer of mannuronic and guluronic acid. Alginate secretion is promoted by the protein Alg44 upon the binding of two c-di-GMP molecules50. The production of alginate is induced under microaerophilic or anaerobic conditions, as is typically the case for chronic infections of COPD and CF lungs51. A recently discovered three-gene operon, sadC-odaA-odaI, controls the oxygen-dependent synthesis of alginate52. During anaerobiosis, the diguanylate cyclase SadC produces c-di-GMP, but in the presence of oxygen OdaI inhibits c-di-GMP synthesis by SadC52. Besides the induction of alginate biosynthesis, SadC inhibits swimming, swarming, and twitching motility, promotes the production of the exopolysaccharide Psl, and is a member of the RetS/LadS/Gac/Rsm regulatory network that constitutes the decision-making switch between sessile and motile lifestyles53,54.
The transition from the biofilm to the planktonic growth state is under the complex regulatory control of many other players influencing the intracellular c-di-GMP levels. The chemosensory protein BdlA, the diguanylate cyclase GcbA, and the c-di-GMP phosphodiesterases DipA, RbdA, and NbdA are known proteins that are required for dispersion to occur55–57.
Within-host evolution of P. aeruginosa
P. aeruginosa may persist for decades in the lungs of individuals with CF, which provides the rare opportunity to study the within-host evolution of a bacterial pathogen for an extended period of time58. A single case who acquired P. aeruginosa in the neonatal period has already been analysed by whole genome sequencing of serial P. aeruginosa isolates more than 10 years ago59. Subsequently, the genetic adaptation of P. aeruginosa to CF lungs has been investigated in carriers of major clones60 or transmissible lineages61–65 and, more recently, in a cohort of CF children who were followed for the early phase of infection66. This study of 474 longitudinal isolates from 34 CF patients seen at the Copenhagen CF clinic, representing 36 different clonal lineages of P. aeruginosa, showed evidence for positive selection at 52 genes, suggesting adaptive evolution to optimise pathogen fitness. Numerous genes encode traits known to be involved in CF lung infection, such as antibiotic resistance or biofilm formation. In our own ongoing work on serial P. aeruginosa isolates from patients seen at the Hannover CF clinic, we rediscovered just a quarter of these 52 candidate pathoadaptive genes to be frequently mutated, demonstrating the versatility of P. aeruginosa to conquer and persist in CF airways. This versatility also shows up in an extensive phenotypic diversity within the P. aeruginosa populations inhabiting CF airways. The analysis of 15 variable traits in 1,720 isolates collected from 10 carriers of the Liverpool epidemic strain revealed 398 unique subtypes67. In summary, all of these cross-sectional and longitudinal studies demonstrated extensive genetic and phenotypic diversity of the P. aeruginosa populations in CF lungs58–72.
The response of the mammalian immune system to P. aeruginosa
Innate immune defence molecules73,74, CD95-mediated apoptosis of epithelial cells75,76, and killing by polymorphonuclear neutrophilic granulocytes (PMNs)77 play critical roles in fighting P. aeruginosa. PMNs are primarily recruited by chemokines to the diseased microenvironment. Upon chemokine binding, the chemokine receptor CXCR2 mediates the migration of the neutrophil to sites of inflammation and the chemokine receptor CXCR1 stimulates the production of reactive oxygen species to kill the P. aeruginosa bacteria78. The clearance of the bacteria, however, should not be accompanied by excessive and systemic inflammation. Recent studies on the cytokines of the interleukin-17 (IL-17) family highlighted this delicate balance between antibacterial host response and inflammation-triggered organ pathology79–81. Through the use of a chronic murine pulmonary infection model, IL-17 cytokine signalling was found to be essential for mouse survival and the prevention of chronic infection with P. aeruginosa79. On the other hand, IL-17A deficiency protected mice from an acute lethal P. aeruginosa lung infection80. In the lung, IL-17A is released from numerous T-cell subtypes, innate lymphoid cells, and macrophages. IL-17A recruits inflammatory cells, but it also activates the airway epithelium to produce IL-17C. IL-17C increases the release of neutrophilic cytokines from alveolar epithelium and thus amplifies inflammation81. IL-17C production is also directly induced by P. aeruginosa. Thus, epithelial cells activated by both the pathogen and the professional immune cells contribute to local and systemic inflammation during P. aeruginosa infection81.
The IL-17 story demonstrates the context-dependent, subtle balance of harm and benefit of host defence mechanisms against P. aeruginosa. The ongoing race between pathogen and host has also resulted in highly specific host responses to individual bacterial components and vice versa. Some key mechanisms have recently been elucidated.
The secondary metabolite phenazine, for example, is recognised by the aryl hydrocarbon receptor AhR that triggers the recruitment of PMNs to the site of the bacterial insult82, whereas the secondary metabolite pyocyanin induces the release of reactive oxygen species from mitochondria, which promotes the death of PMNs83. These key cells of host defence not only eliminate P. aeruginosa by phagocytic killing but also trap and kill the microbes by neutrophilic extracellular traps (NETs), which are made up of DNA as the scaffold and neutrophilic granule components such as neutrophil elastase and myeloperoxidase84,85. The flagellum has been shown to be the main bacterial organelle that induces NET formation and thus triggers inflammation86. Early growth phase P. aeruginosa are the strongest NET inducers. On the other hand, flagellar motility is downregulated and the flagellum is even lost during the course of chronic lung infections so that P. aeruginosa evades NET-mediated killing86–88.
If P. aeruginosa conquers a mammalian niche, it delivers the T3SS effector molecule ExoS directly into the cytosol of the host cell. In a mouse pneumonia model, phagocytes were targeted for injection of ExoS early during infection followed by injection of epithelial cells at later time points so that finally the pulmonary–vascular barrier was disrupted89. This mechanism of stepwise inactivation of host defence cells first and the epithelial barrier thereafter makes it plausible that P. aeruginosa bacteria in the lung can gain access to the bloodstream and cause sepsis.
Looking back forward
P. aeruginosa has been and still is one of the medically most relevant opportunistic pathogens in man2,90,91. The management of eye92 and burn wound93,94 infections has made considerable progress, but the acute95 and chronic4,5,95–99 pulmonary infections continue to be associated with substantial morbidity and mortality.
Thanks to the application of omics technologies, we have gained insight into P. aeruginosa’s genome organisation and diversity8,10,11,22,100, habitat-specific transcriptome101–105, proteome106–108, and metabolome108–112 and the co-evolution of P. aeruginosa with competitors in human habitats such as Staphylococcus aureus113–115. The function of hundreds of previously uncharacterised “conserved hypotheticals”11 and the structure of secretory nanomachines have been resolved37,41,116–121 and knowledge has been gained about the complex regulation of the release of exopolysaccharides, secondary metabolites, and virulence effectors1. In other words, during the last few years, we have learnt a lot about the modules of bacterial pathogenicity1,122. In contrast, progress has been rather slow in the field of antipseudomonal host defence. The mechanisms that mediate bacterial clearance without causing excessive immune pathology deserve further investigation if we want to improve the management of Pseudomonas pneumonia and sepsis123–126. P. aeruginosa is an extremely versatile microorganism, and it will continue to surprise us with as-yet-unappreciated modes of niche adaptation, lifestyle, and pathogenicity.
Competing interests
The authors declare that they have no competing interests.
Grant information
The authors’ work on P. aeruginosa genomics, microevolution, and pathogenicity has been supported by the Bundesministerium für Forschung und Technologie BMBF (FKZ 0315827D) and the Deutsche Forschungsgemeinschaft (SFB 900, projects A2 and Z1).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Faculty Opinions recommended
References
1.
Ramos JL (ed.):
Pseudomonas. Heidelberg: Springer; 2004; 1–7. Publisher Full Text
2.
Buhl M, Peter S, Willmann M:
Prevalence and risk factors associated with colonization and infection of extensively drug-resistant Pseudomonas aeruginosa: a systematic review.
Expert Rev Anti Infect Ther.
2015; 13(9): 1159–70. PubMed Abstract
| Publisher Full Text
3.
Gonçalves-de-Albuquerque CF, Silva AR, Burth P, et al.:
Possible mechanisms of Pseudomonas aeruginosa-associated lung disease.
Int J Med Microbiol.
2016; 306(1): 20–8. PubMed Abstract
| Publisher Full Text
4.
Talwalkar JS, Murray TS:
The Approach to Pseudomonas aeruginosa in Cystic Fibrosis.
Clin Chest Med.
2016; 37(1): 69–81. PubMed Abstract
| Publisher Full Text
5.
Murphy TF:
Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease.
Curr Opin Pulm Med.
2009; 15(2): 138–42. PubMed Abstract
| Publisher Full Text
6.
Balasubramanian D, Schneper L, Kumari H, et al.:
A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence.
Nucleic Acids Res.
2013; 41(1): 1–20. PubMed Abstract
| Publisher Full Text
| Free Full Text
7.
Reinhart AA, Oglesby-Sherrouse AG:
Regulation of Pseudomonas aeruginosa Virulence by Distinct Iron Sources.
Genes (Basel).
2016; 7(12): pii: E126. PubMed Abstract
| Publisher Full Text
| Free Full Text
8.
Hilker R, Munder A, Klockgether J, et al.:
Interclonal gradient of virulence in the Pseudomonas aeruginosa pangenome from disease and environment.
Environ Microbiol.
2015; 17(1): 29–46. PubMed Abstract
| Publisher Full Text
9.
Wiehlmann L, Cramer N, Tümmler B:
Habitat-associated skew of clone abundance in the Pseudomonas aeruginosa population.
Environ Microbiol Rep.
2015; 7(6): 955–60. PubMed Abstract
| Publisher Full Text
10.
Fischer S, Klockgether J, Morán Losada P, et al.:
Intraclonal genome diversity of the major Pseudomonas aeruginosa clones C and PA14.
Environ Microbiol Rep.
2016; 8(2): 227–34. PubMed Abstract
| Publisher Full Text
| Free Full Text
11.
Winsor GL, Griffiths EJ, Lo R, et al.:
Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database.
Nucleic Acids Res.
2016; 44(D1): D646–53. PubMed Abstract
| Publisher Full Text
| Free Full Text
12.
Sonnleitner E, Haas D:
Small RNAs as regulators of primary and secondary metabolism in Pseudomonas species.
Appl Microbiol Biotechnol.
2011; 91(1): 63–79. PubMed Abstract
| Publisher Full Text
13.
Sonnleitner E, Bläsi U:
Regulation of Hfq by the RNA CrcZ in Pseudomonas aeruginosa carbon catabolite repression.
PLoS Genet.
2014; 10(6): e1004440. PubMed Abstract
| Publisher Full Text
| Free Full Text
14.
Pusic P, Tata M, Wolfinger MT, et al.:
Cross-regulation by CrcZ RNA controls anoxic biofilm formation in Pseudomonas aeruginosa.
Sci Rep.
2016; 6: 39621. PubMed Abstract
| Publisher Full Text
| Free Full Text
15.
Chambonnier G, Roux L, Redelberger D, et al.:
The Hybrid Histidine Kinase LadS Forms a Multicomponent Signal Transduction System with the GacS/GacA Two-Component System in Pseudomonas aeruginosa.
PLoS Genet.
2016; 12(5): e1006032. PubMed Abstract
| Publisher Full Text
| Free Full Text
17.
Galle M, Carpentier I, Beyaert R:
Structure and function of the Type III secretion system of Pseudomonas aeruginosa.
Curr Protein Pept Sci.
2012; 13(8): 831–42. PubMed Abstract
| Publisher Full Text
| Free Full Text
19.
Engel J, Balachandran P:
Role of Pseudomonas aeruginosa type III effectors in disease.
Curr Opin Microbiol.
2009; 12(1): 61–6. PubMed Abstract
| Publisher Full Text
21.
Sawa T, Hamaoka S, Kinoshita M, et al.:
Pseudomonas aeruginosa Type III Secretory Toxin ExoU and Its Predicted Homologs.
Toxins (Basel).
2016; 8(11): pii: E307. PubMed Abstract
| Publisher Full Text
| Free Full Text
22.
Freschi L, Jeukens J, Kukavica-Ibrulj I, et al.:
Clinical utilization of genomics data produced by the international Pseudomonas aeruginosa consortium.
Front Microbiol.
2015; 6: 1036. PubMed Abstract
| Publisher Full Text
| Free Full Text
23.
Salacha R, Kovacić F, Brochier-Armanet C, et al.:
The Pseudomonas aeruginosa patatin-like protein PlpD is the archetype of a novel Type V secretion system.
Environ Microbiol.
2010; 12(6): 1498–512. PubMed Abstract
| Publisher Full Text
24.
da Mata Madeira PV, Zouhir S, Basso P, et al.:
Structural Basis of Lipid Targeting and Destruction by the Type V Secretion System of Pseudomonas aeruginosa.
J Mol Biol.
2016; 428(9 Pt A): 1790–803. PubMed Abstract
| Publisher Full Text
26.
Wood SJ, Goldufsky JW, Bello D, et al.:
Pseudomonas aeruginosa ExoT Induces Mitochondrial Apoptosis in Target Host Cells in a Manner That Depends on Its GTPase-activating Protein (GAP) Domain Activity.
J Biol Chem.
2015; 290(48): 29063–73. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
28.
Yahr TL, Vallis AJ, Hancock MK, et al.:
ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system.
Proc Natl Acad Sci U S A.
1998; 95(23): 13899–904. PubMed Abstract
| Publisher Full Text
| Free Full Text
29.
Morrow KA, Seifert R, Kaever V, et al.:
Heterogeneity of pulmonary endothelial cyclic nucleotide response to Pseudomonas aeruginosa ExoY infection.
Am J Physiol Lung Cell Mol Physiol.
2015; 309(10): L1199–207. PubMed Abstract
| Publisher Full Text
| Free Full Text
30.
Morrow KA, Ochoa CD, Balczon R, et al.:
Pseudomonas aeruginosa exoenzymes U and Y induce a transmissible endothelial proteinopathy.
Am J Physiol Lung Cell Mol Physiol.
2016; 310(4): L337–53. PubMed Abstract
| Publisher Full Text
| Free Full Text
31.
Belyy A, Raoux-Barbot D, Saveanu C, et al.:
Actin activates Pseudomonas aeruginosa ExoY nucleotidyl cyclase toxin and ExoY-like effector domains from MARTX toxins.
Nat Commun.
2016; 7: 13582. PubMed Abstract
| Publisher Full Text
| Free Full Text
33.
Huber P, Basso P, Reboud E, et al.:
Pseudomonas aeruginosa renews its virulence factors.
Environ Microbiol Rep.
2016; 8(5): 564–571. PubMed Abstract
| Publisher Full Text
34.
Thrane SW, Taylor VL, Freschi L, et al.:
The Widespread Multidrug-Resistant Serotype O12 Pseudomonas aeruginosa Clone Emerged through Concomitant Horizontal Transfer of Serotype Antigen and Antibiotic Resistance Gene Clusters.
MBio.
2015; 6(5): e01396–15. PubMed Abstract
| Publisher Full Text
| Free Full Text
| Faculty Opinions Recommendation
35.
Elsen S, Huber P, Bouillot S, et al.:
A type III secretion negative clinical strain of Pseudomonas aeruginosa employs a two-partner secreted exolysin to induce hemorrhagic pneumonia.
Cell Host Microbe.
2014; 15(2): 164–76. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
36.
Reboud E, Elsen S, Bouillot S, et al.:
Phenotype and toxicity of the recently discovered exlA-positive Pseudomonas aeruginosa strains collected worldwide.
Environ Microbiol.
2016; 18(10): 3425–39. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
37.
Chen L, Zou Y, She P, et al.:
Composition, function, and regulation of T6SS in Pseudomonas aeruginosa.
Microbiol Res.
2015; 172: 19–25. PubMed Abstract
| Publisher Full Text
38.
Lin J, Cheng J, Chen K, et al.:
The icmF3 locus is involved in multiple adaptation- and virulence-related characteristics in Pseudomonas aeruginosa PAO1.
Front Cell Infect Microbiol.
2015; 5: 70. PubMed Abstract
| Publisher Full Text
| Free Full Text
39.
Jiang F, Waterfield NR, Yang J, et al.:
A Pseudomonas aeruginosa type VI secretion phospholipase D effector targets both prokaryotic and eukaryotic cells.
Cell Host Microbe.
2014; 15(5): 600–10. PubMed Abstract
| Publisher Full Text
40.
Hu H, Zhang H, Gao Z, et al.:
Structure of the type VI secretion phospholipase effector Tle1 provides insight into its hydrolysis and membrane targeting.
Acta Crystallogr D Biol Crystallogr.
2014; 70(Pt 8): 2175–85. PubMed Abstract
| Publisher Full Text
41.
Yang XY, Li ZQ, She Z, et al.:
Structural analysis of Pseudomonas aeruginosa H3-T6SS immunity proteins.
FEBS Lett.
2016; 590(16): 2787–96. PubMed Abstract
| Publisher Full Text
42.
Flaugnatti N, Le TT, Canaan S, et al.:
A phospholipase A1 antibacterial Type VI secretion effector interacts directly with the C-terminal domain of the VgrG spike protein for delivery.
Mol Microbiol.
2016; 99(6): 1099–118. PubMed Abstract
| Publisher Full Text
43.
Jiang F, Wang X, Wang B, et al.:
The Pseudomonas aeruginosa Type VI Secretion PGAP1-like Effector Induces Host Autophagy by Activating Endoplasmic Reticulum Stress.
Cell Rep.
2016; 16(6): 1502–9. PubMed Abstract
| Publisher Full Text
46.
Ha DG, O'Toole GA:
c-di-GMP and its Effects on Biofilm Formation and Dispersion: a Pseudomonas Aeruginosa Review.
Microbiol Spectr.
2015; 3(2): MB-0003-2014. PubMed Abstract
| Publisher Full Text
| Free Full Text
47.
Valentini M, Filloux A:
Biofilms and Cyclic di-GMP (c-di-GMP) Signaling: Lessons from Pseudomonas aeruginosa and Other Bacteria.
J Biol Chem.
2016; 291(24): 12547–55. PubMed Abstract
| Publisher Full Text
| Free Full Text
50.
Whitney JC, Whitfield GB, Marmont LS, et al.:
Dimeric c-di-GMP is required for post-translational regulation of alginate production in Pseudomonas aeruginosa.
J Biol Chem.
2015; 290(20): 12451–62. PubMed Abstract
| Publisher Full Text
| Free Full Text
51.
Worlitzsch D, Tarran R, Ulrich M, et al.:
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
J Clin Invest.
2002; 109(3): 317–25. PubMed Abstract
| Publisher Full Text
| Free Full Text
52.
Schmidt A, Hammerbacher AS, Bastian M, et al.:
Oxygen-dependent regulation of c-di-GMP synthesis by SadC controls alginate production in Pseudomonas aeruginosa.
Environ Microbiol.
2016; 18(10): 3390–402. PubMed Abstract
| Publisher Full Text
53.
Moscoso JA, Jaeger T, Valentini M, et al.:
The diguanylate cyclase SadC is a central player in Gac/Rsm-mediated biofilm formation in Pseudomonas aeruginosa.
J Bacteriol.
2014; 196(23): 4081–8. PubMed Abstract
| Publisher Full Text
| Free Full Text
54.
Zhu B, Liu C, Liu S, et al.:
Membrane association of SadC enhances its diguanylate cyclase activity to control exopolysaccharides synthesis and biofilm formation in Pseudomonas aeruginosa.
Environ Microbiol.
2016; 18(10): 3440–52. PubMed Abstract
| Publisher Full Text
| Faculty Opinions Recommendation
55.
Basu Roy A, Sauer K:
Diguanylate cyclase NicD-based signalling mechanism of nutrient-induced dispersion by Pseudomonas aeruginosa.
Mol Microbiol.
2014; 94(4): 771–93. PubMed Abstract
| Publisher Full Text
| Free Full Text
56.
Li Y, Petrova OE, Su S, et al.:
BdlA, DipA and induced dispersion contribute to acute virulence and chronic persistence of Pseudomonas aeruginosa.
PLoS Pathog.
2014; 10(6): e1004168. PubMed Abstract
| Publisher Full Text
| Free Full Text
60.
Cramer N, Klockgether J, Wrasman K, et al.:
Microevolution of the major common Pseudomonas aeruginosa clones C and PA14 in cystic fibrosis lungs.
Environ Microbiol.
2011; 13(7): 1690–704. PubMed Abstract
| Publisher Full Text
63.
Williams D, Evans B, Haldenby S, et al.:
Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections.
Am J Respir Crit Care Med.
2015; 191(7): 775–85. PubMed Abstract
| Publisher Full Text
| Free Full Text
64.
Dettman JR, Rodrigue N, Aaron SD, et al.:
Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa.
Proc Natl Acad Sci U S A.
2013; 110(52): 21065–70. PubMed Abstract
| Publisher Full Text
| Free Full Text
65.
Sherrard LJ, Tai AS, Wee BA, et al.:
Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis.
PLoS One.
2017; 12(3): e0172179. PubMed Abstract
| Publisher Full Text
| Free Full Text
67.
Mowat E, Paterson S, Fothergill JL, et al.:
Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections.
Am J Respir Crit Care Med.
2011; 183(12): 1674–9. PubMed Abstract
| Publisher Full Text
68.
Workentine ML, Sibley CD, Glezerson B, et al.:
Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient.
PLoS One.
2013; 8(4): e60225. PubMed Abstract
| Publisher Full Text
| Free Full Text
69.
Clark ST, Diaz Caballero J, Cheang M, et al.:
Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis.
Sci Rep.
2015; 5: 10932. PubMed Abstract
| Publisher Full Text
| Free Full Text
70.
Marvig RL, Sommer LM, Jelsbak L, et al.:
Evolutionary insight from whole-genome sequencing of Pseudomonas aeruginosa from cystic fibrosis patients.
Future Microbiol.
2015; 10(4): 599–611. PubMed Abstract
| Publisher Full Text
71.
Andersen SB, Marvig RL, Molin S, et al.:
Long-term social dynamics drive loss of function in pathogenic bacteria.
Proc Natl Acad Sci U S A.
2015; 112(34): 10756–61. PubMed Abstract
| Publisher Full Text
| Free Full Text
73.
Wnorowska U, Niemirowicz K, Myint M, et al.:
Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.
Antimicrob Agents Chemother.
2015; 59(7): 3808–15. PubMed Abstract
| Publisher Full Text
| Free Full Text
74.
Wonnenberg B, Bischoff M, Beisswenger C, et al.:
The role of IL-1β in Pseudomonas aeruginosa in lung infection.
Cell Tissue Res.
2016; 364(2): 225–9. PubMed Abstract
| Publisher Full Text
75.
Grassmé H, Kirschnek S, Riethmueller J, et al.:
CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa.
Science.
2000; 290(5491): 527–30. PubMed Abstract
| Publisher Full Text
77.
Lovewell RR, Patankar YR, Berwin B:
Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa.
Am J Physiol Lung Cell Mol Physiol.
2014; 306(7): L591–603. PubMed Abstract
| Publisher Full Text
| Free Full Text
83.
Managò A, Becker KA, Carpinteiro A, et al.:
Pseudomonas aeruginosa pyocyanin induces neutrophil death via mitochondrial reactive oxygen species and mitochondrial acid sphingomyelinase.
Antioxid Redox Signal.
2015; 22(13): 1097–110. PubMed Abstract
| Publisher Full Text
| Free Full Text
85.
Yoo DG, Floyd M, Winn M, et al.:
NET formation induced by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of myeloperoxidase-DNA and neutrophil elastase-DNA complexes.
Immunol Lett.
2014; 160(2): 186–94. PubMed Abstract
| Publisher Full Text
87.
Young RL, Malcolm KC, Kret JE, et al.:
Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.
PLoS One.
2011; 6(9): e23637. PubMed Abstract
| Publisher Full Text
| Free Full Text
88.
Luzar MA, Thomassen MJ, Montie TC:
Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition.
Infect Immun.
1985; 50(2): 577–82. PubMed Abstract
| Free Full Text
90.
Kaye KS, Pogue JM:
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.
Pharmacotherapy.
2015; 35(10): 949–62. PubMed Abstract
| Publisher Full Text
91.
Oliver A, Mulet X, López-Causapé C, et al.:
The increasing threat of Pseudomonas aeruginosa high-risk clones.
Drug Resist Updat.
2015; 21–22: 41–59. PubMed Abstract
| Publisher Full Text
92.
Willcox MD:
Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review.
Optom Vis Sci.
2007; 84(4): 273–8. PubMed Abstract
| Publisher Full Text
94.
Fournier A, Voirol P, Krähenbühl M, et al.:
Antibiotic consumption to detect epidemics of Pseudomonas aeruginosa in a burn centre: A paradigm shift in the epidemiological surveillance of Pseudomonas aeruginosa nosocomial infections.
Burns.
2016; 42(3): 564–70. PubMed Abstract
| Publisher Full Text
95.
Bassi GL, Ferrer M, Marti JD, et al.:
Ventilator-associated pneumonia.
Semin Respir Crit Care Med.
2014; 35(4): 469–81. PubMed Abstract
| Publisher Full Text
96.
Novosad SA, Barker AF:
Chronic obstructive pulmonary disease and bronchiectasis.
Curr Opin Pulm Med.
2013; 19(2): 133–9. PubMed Abstract
| Publisher Full Text
97.
Döring G, Parameswaran IG, Murphy TF:
Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease.
FEMS Microbiol Rev.
2011; 35(1): 124–46. PubMed Abstract
| Publisher Full Text
98.
Langan KM, Kotsimbos T, Peleg AY:
Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis.
Curr Opin Infect Dis.
2015; 28(6): 547–56. PubMed Abstract
| Publisher Full Text
102.
Turner KH, Everett J, Trivedi U, et al.:
Requirements for Pseudomonas aeruginosa acute burn and chronic surgical wound infection.
PLoS Genet.
2014; 10(7): e1004518. PubMed Abstract
| Publisher Full Text
| Free Full Text
103.
Dötsch A, Schniederjans M, Khaledi A, et al.:
The Pseudomonas aeruginosa Transcriptional Landscape Is Shaped by Environmental Heterogeneity and Genetic Variation.
MBio.
2015; 6(4): e00749. PubMed Abstract
| Publisher Full Text
| Free Full Text
104.
Kruczek C, Kottapalli KR, Dissanaike S, et al.:
Major Transcriptome Changes Accompany the Growth of Pseudomonas aeruginosa in Blood from Patients with Severe Thermal Injuries.
PLoS One.
2016; 11(3): e0149229. PubMed Abstract
| Publisher Full Text
| Free Full Text
105.
Karna SL, D'Arpa P, Chen T, et al.:
RNA-Seq Transcriptomic Responses of Full-Thickness Dermal Excision Wounds to Pseudomonas aeruginosa Acute and Biofilm Infection.
PLoS One.
2016; 11(10): e0165312. PubMed Abstract
| Publisher Full Text
| Free Full Text
106.
Kamath KS, Pascovici D, Penesyan A, et al.:
Pseudomonas aeruginosa Cell Membrane Protein Expression from Phenotypically Diverse Cystic Fibrosis Isolates Demonstrates Host-Specific Adaptations.
J Proteome Res.
2016; 15(7): 2152–63. PubMed Abstract
| Publisher Full Text
107.
Krueger J, Pohl S, Preusse M, et al.:
Unravelling post-transcriptional PrmC-dependent regulatory mechanisms in Pseudomonas aeruginosa.
Environ Microbiol.
2016; 18(10): 3583–92. PubMed Abstract
| Publisher Full Text
108.
Lassek C, Berger A, Zühlke D, et al.:
Proteome and carbon flux analysis of Pseudomonas aeruginosa clinical isolates from different infection sites.
Proteomics.
2016; 16(9): 1381–5. PubMed Abstract
| Publisher Full Text
109.
Frimmersdorf E, Horatzek S, Pelnikevich A, et al.:
How Pseudomonas aeruginosa adapts to various environments: a metabolomic approach.
Environ Microbiol.
2010; 12(6): 1734–47. PubMed Abstract
| Publisher Full Text
110.
Behrends V, Bell TJ, Liebeke M, et al.:
Metabolite profiling to characterize disease-related bacteria: gluconate excretion by Pseudomonas aeruginosa mutants and clinical isolates from cystic fibrosis patients.
J Biol Chem.
2013; 288(21): 15098–109. PubMed Abstract
| Publisher Full Text
| Free Full Text
111.
Tielen P, Rosin N, Meyer AK, et al.:
Regulatory and metabolic networks for the adaptation of Pseudomonas aeruginosa biofilms to urinary tract-like conditions.
PLoS One.
2013; 8(8): e71845. PubMed Abstract
| Publisher Full Text
112.
Okon E, Dethlefsen S, Pelnikevich A, et al.:
Key role of an ADP - ribose - dependent transcriptional regulator of NAD metabolism for fitness and virulence of Pseudomonas aeruginosa.
Int J Med Microbiol.
2017; 307(1): 83–94. PubMed Abstract
| Publisher Full Text
117.
Izoré T, Perdu C, Job V, et al.:
Structural characterization and membrane localization of ExsB from the type III secretion system (T3SS) of Pseudomonas aeruginosa.
J Mol Biol.
2011; 413(1): 236–46. PubMed Abstract
| Publisher Full Text
118.
Gendrin C, Contreras-Martel C, Bouillot S, et al.:
Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa.
PLoS Pathog.
2012; 8(4): e1002637. PubMed Abstract
| Publisher Full Text
| Free Full Text
119.
Discola KF, Förster A, Boulay F, et al.:
Membrane and chaperone recognition by the major translocator protein PopB of the type III secretion system of Pseudomonas aeruginosa.
J Biol Chem.
2014; 289(6): 3591–601. PubMed Abstract
| Publisher Full Text
| Free Full Text
120.
Lu D, Shang G, Zhang H, et al.:
Structural insights into the T6SS effector protein Tse3 and the Tse3-Tsi3 complex from Pseudomonas aeruginosa reveal a calcium-dependent membrane-binding mechanism.
Mol Microbiol.
2014; 92(5): 1092–112. PubMed Abstract
| Publisher Full Text
122.
Lorenz A, Pawar V, Häussler S, et al.:
Insights into host-pathogen interactions from state-of-the-art animal models of respiratory Pseudomonas aeruginosa infections.
FEBS Lett.
2016; 590(21): 3941–59. PubMed Abstract
| Publisher Full Text
123.
Micek ST, Wunderink RG, Kollef MH, et al.:
An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.
Crit Care.
2015; 19: 219. PubMed Abstract
| Publisher Full Text
| Free Full Text
124.
Micek ST, Kollef MH, Torres A, et al.:
Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification.
Infect Control Hosp Epidemiol.
2015; 36(10): 1190–7. PubMed Abstract
| Publisher Full Text
125.
Cillóniz C, Gabarrús A, Ferrer M, et al.:
Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant Pseudomonas aeruginosa.
Chest.
2016; 150(2): 415–25. PubMed Abstract
| Publisher Full Text
126.
Fernández-Barat L, Ferrer M, de Rosa F, et al.:
Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
J Infect.
2017; 74(2): 142–52. PubMed Abstract
| Publisher Full Text
1
Molecular Pathology of Cystic Fibrosis Clinical Research Group, Clinic for Paediatric Pneumology, Allergology, and Neonatology, OE 6710, Hannover Medical School, Hannover, Germany 2
Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Centre for Lung Research, Hannover, Germany
The authors’ work on P. aeruginosa genomics, microevolution, and pathogenicity has been supported by the Bundesministerium für Forschung und Technologie BMBF (FKZ 0315827D) and the Deutsche Forschungsgemeinschaft (SFB 900, projects A2 and Z1).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Klockgether J and Tümmler B. Recent advances in understanding Pseudomonas aeruginosa as a pathogen [version 1; peer review: 3 approved] F1000Research 2017, 6(F1000 Faculty Rev):1261 (https://doi.org/10.12688/f1000research.10506.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Share
Open Peer Review
Current Reviewer Status:
?
Key to Reviewer Statuses
VIEWHIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Adjust parameters to alter display
View on desktop for interactive features
Includes Interactive Elements
View on desktop for interactive features
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Comments on this article Comments (0)